1-7 of 7
Henning Walczak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B13: The impact of combined CDK9 inhibition and TRAIL treatment on NSCLC

Itziar Areso Zubiaur, Antonella Montinaro, Silvia von Karstedt, Johannes Lemke, Torsten Hartwig, Lucia Taraborelli, Silvia Surinova, Mona A. El-Bahrawy, Henning Walczak
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B13.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B13
Published: 01 September 2018
View article titled, Abstract B13: The impact of combined CDK9 inhibition and TRAIL treatment on NSCLC
Journal Articles

Abstract B18: Characterization and therapeutic harnessing of TRAIL’s pro-tumorigenic and pro-apoptotic functions in cancer

Antonella Montinaro, Torsten Hartwig, Silvia von Karstedt, Itziar Areso Zubiaur, Johannes Lemke, Lucia Taraborelli, Silvia Surinova, Mona A. El-Bahrawy, Henning Walczak
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B18.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B18
Published: 01 September 2018
View article titled, Abstract B18: Characterization and therapeutic harnessing of TRAIL’s pro-tumorigenic and pro-apoptotic functions in cancer
Journal Articles

Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer

Stephan Macher-Goeppinger, Sebastian Aulmann, Katrin E. Tagscherer, Nina Wagener, Axel Haferkamp, Roland Penzel, Antje Brauckhoff, Markus Hohenfellner, Jaromir Sykora, Henning Walczak, Bin T. Teh, Frank Autschbach, Esther Herpel, Peter Schirmacher, Wilfried Roth
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 650–659.
https://doi.org/10.1158/1078-0432.CCR-08-0284
Published: 15 January 2009
View article titled, Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
Open the PDF for Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL

Ronald Koschny, Jaromir Sykora, Henning Walczak, Tom M. Ganten, Tobias L. Haas, Martin R. Sprick, Heidrum Holland, Peter Ahnert, Wolfgang Krupp, Jürgen Meixensberger, Manfred Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6541–6542.
https://doi.org/10.1158/1078-0432.CCR-07-1759
Published: 01 November 2007
View article titled, Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL
Open the PDF for Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL in another window
Journal Articles

Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

Ronald Koschny, Heidrun Holland, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Tom M. Ganten, Wolfgang Krupp, Manfred Bauer, Peter Ahnert, Jürgen Meixensberger, Henning Walczak
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3403–3412.
https://doi.org/10.1158/1078-0432.CCR-07-0251
Published: 01 June 2007
View article titled, Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
Open the PDF for Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in another window
Journal Articles

Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs

Tom M. Ganten, Ronald Koschny, Jaromir Sykora, Henning Schulze-Bergkamen, Peter Büchler, Tobias L. Haas, Manuela B. Schader, Andreas Untergasser, Wolfgang Stremmel, Henning Walczak
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (8): 2640–2646.
https://doi.org/10.1158/1078-0432.CCR-05-2635
Published: 25 April 2006
View article titled, Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs
Open the PDF for Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs in another window
Journal Articles

Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter

Jörn Sträter, Ulf Hinz, Henning Walczak, Gunhild Mechtersheimer, Karin Koretz, Christian Herfarth, Peter Möller, Thomas Lehnert
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3734–3740.
Published: 01 December 2002
View article titled, Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter
Open the PDF for Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter in another window